Ahmedabad-basedZydus Lifesciences Limitedis set to make a major move in the IndianGLP-1 therapymarket with the launch of its genericsemaglutide injectionimmediately after the drug’s patent expires in late March 2026 — a strategy that could significantly expand access to advanced diabetes and obesity treatment. Semaglutide, aGLP-1 receptor agonist, is widely prescribed globally to improve blood sugar control and support weight loss in patients with Type 2 diabetes and chronic obesity.

Zydus will roll out the therapy under three brand names —SEMAGLYN™, MASHEMA™ and ALTERME™ —in a15 mg/3 mlstrength and has developed an innovativeadjustable reusable single-pen delivery device. This device allows patients to select different dose strengths using a single pen, avoiding the need to buy multiple single-use pens during dose titration. The company holdsexclusive rightsto this novel delivery system in India, which is expected to lower overall treatment costs and improve patient adherence — crucial for chronic, long-term therapy.

The approval from theDrug Controller General of India (DCGI)to manufacture and market semaglutide formulations reflects the regulator’s support for increasing local access to high-impact therapies. As semaglutide’s patent expires, Zydus’ early launch positions it to compete strongly with existing global GLP-1 therapies that have been priced at a premium and seen limited accessibility for many patients in India. Analysts expect broader competition as domestic players gear up for generics, which could potentially lead to price reductions and wider adoption of GLP-1 therapies nationwide.